VANCOUVER, B.C., CANADA – Dec. 14, 2011 – Biolux Research Ltd. is pleased to announce that it has raised CAD $2.4MM in new funding for the company. The funds were raised through a debt issue that is convertible to common shares at the company’s option, and was fully subscribed by existing shareholders of the company.

The proceeds of the financing are designated as working capital to continue the development of the OrthoPulse™, a full mouth, extra-oral phototherapy device designed to compliment traditional orthodontic treatment, and facilitate faster tooth movement and reduced treatment timelines. The funds are also targeted to complete initial orthodontic human trials and expand the clinical roadmap of new studies and trials, and to develop new technology and additional intellectual property. The new funds are anticipated to support the company through to the commercial launch of the OrthoPulse™.

“We are very pleased with the confidence of our shareholder group in our progress towards the light accelerated orthodontics market,” states Kevin Strange, President and CEO of Biolux. “Our development program to date has produced impressive scientific and clinical results, and we are greatly encouraged by the interest in and support by the orthodontic community. We strongly believe that addressing the biological factors of bone regeneration, the rate limiting factors in tooth movement, is the next frontier in orthodontics, and we feel that our technology will both improve the quality of tooth movement and dramatically reduce orthodontic treatment timelines. We expect to revolutionize the orthodontics market for patients and orthodontists, and we look forward to further increasing shareholder value as we explore options for commercialization of the new product.”

About Biolux Research

Biolux Research Ltd. is a world leader in the development of innovative Light Accelerated Regeneration technologies and products for use in orthodontics, implantology, and other dentistry markets. Biolux focuses on phototherapy product development and clinical research, and its proprietary, patent-pending technologies have been developed to enhance clinical outcomes and dramatically reduce treatment timelines in dentistry in a safe, effective and non-invasive approach. www.bioluxresearch.com

For More Information:

Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com